drugset / Trial / NCT02545907
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis. The trial begins with a dose escalation phase, in which the maximum tolerated and recommended dose will be determined. The trial will then open into an expansion phase in which the combination efficacy is assessed.
Timeline
- Start
- 2017-09-14
- Primary completion
- 2019-09-26
- Completion
- 2019-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 27 mg/m2 | — |
| Subject | Carfilzomib | Other / unclassified | 36 mg/m2 | — |
| Subject | Carfilzomib | Other / unclassified | 45 mg/m2 | — |
| Subject | Carfilzomib | Other / unclassified | 56 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Thalidomide | Other / unclassified | 50 mg | — |